Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blonanserin vs Risperidone in Schizophrenia
NCT01516424Phase 3Completed
- Sponsor
- Sumitomo Pharma
- Start
- Feb 2012
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of blonanserin in schizophrenia (2 arms), sponsored by Sumitomo Pharma. Primary endpoint: Positive and Negative Syndrome Scale Total Score at Week 8. Started Feb 2012; status: completed.
02
Drugs
blonanserin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01516424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01516424.